Karuna Therapeutics, Inc. (NASDAQ:KRTX) Receives $275.44 Consensus Target Price from Brokerages

Shares of Karuna Therapeutics, Inc. (NASDAQ:KRTX – Get Free Report) have been assigned an average recommendation of “Moderate Buy” from the fifteen brokerages that are covering the firm, Marketbeat reports. Two investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. The average 1 year […]

Related Keywords

Cambridge ,Cambridgeshire ,United Kingdom ,Lauriej Olson ,Andrew Craig Miller ,Nasdaq ,Cambridge Investment Research Advisors Inc ,Metlife Investment Management ,York Mellon Corp ,Karuna Therapeutics Inc ,Jpmorgan Chase Co ,Karuna Therapeutics ,Get Free Report ,Director Laurie ,Craig Miller ,New York Mellon Corp ,Investment Research Advisors ,Life Investment Management ,Rhumbline Advisers ,Get Free ,Karuna Therapeutics Daily ,